|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
California Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing CaliforniaLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Pearl Therapeutics Inc.
| | | Phone: | (650) 305-2600 | Fax: | (650) 568-1804 | Year Established: | 2006 | Main Contact: | Colin Reisner, MD, FCCP, FAAAAI, President & CEO | | Other Contacts: | Sarvajna Dwivedi, Ph.D., Co-Founder & CSO Michael Riebe, Ph.D., VP, Inhalation Product Development, AstraZeneca Michael Golden, Senior VP, Regulatory Affairs & Quality
| | Company Description | Pearl's mission is to develop differentiated therapeutics for respiratory disease conditions prevalent worldwide, including chronic obstructive pulmonary disease (COPD). The product candidates currently being developed are based on the simple and widely prescribed metered-dose inhaler (MDI) dosage form. Company scientists have invented a novel Co-SuspensionTM Delivery Technology for use with MDIs that enables efficient targeting and distribution of drug to the lungs. | |
|
|
|
|
|